CHARLES RIV LABS INTL INC's ticker is CRL and the CUSIP is 159864107. A total of 656 filers reported holding CHARLES RIV LABS INTL INC in Q2 2024. The put-call ratio across all filers is 1.01 and the average weighting 0.2%.
About CHARLES RIV LABS INTL INC
Charles River Laboratories International Inc. is a leading provider of research products and services to the pharmaceutical, biotechnology, and medical device industries. The company has a global presence, with operations in North America, Europe, and Asia-Pacific.
Charles River Laboratories International Inc. offers a wide range of services, including drug discovery and development, safety assessment, and clinical support services. The company's expertise in these areas has made it a trusted partner for many of the world's leading pharmaceutical and biotechnology companies.
One of the key strengths of Charles River Laboratories International Inc. is its commitment to innovation. The company invests heavily in research and development, and has a track record of developing new products and services that meet the evolving needs of its customers.
Another important factor in the company's success is its focus on quality. Charles River Laboratories International Inc. has a rigorous quality control system in place, which ensures that its products and services meet the highest standards of safety and efficacy.
Overall, Charles River Laboratories International Inc. is a well-respected and highly regarded company in the pharmaceutical and biotechnology industries. Its commitment to innovation and quality has helped it to maintain a leading position in these markets, and it is well positioned to continue to grow and succeed in the years ahead.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $274,373 | -6.8% | 1,400 | 0.0% | 0.01% | 0.0% |
| Q2 2023 | $294,350 | +4.2% | 1,400 | 0.0% | 0.01% | +20.0% |
| Q1 2023 | $282,549 | -27.8% | 1,400 | -22.0% | 0.01% | -37.5% |
| Q4 2022 | $391,131 | -22.1% | 1,795 | -29.5% | 0.01% | -20.0% |
| Q3 2022 | $502,000 | -95.8% | 2,547 | -95.5% | 0.01% | -95.5% |
| Q2 2022 | $12,096,000 | -30.9% | 56,528 | -8.3% | 0.22% | -16.0% |
| Q1 2022 | $17,498,000 | -31.9% | 61,614 | -9.7% | 0.26% | -20.4% |
| Q4 2021 | $25,698,000 | -17.2% | 68,200 | -9.3% | 0.33% | -19.0% |
| Q3 2021 | $31,034,000 | -8.0% | 75,200 | -17.6% | 0.41% | +5.5% |
| Q2 2021 | $33,743,000 | +34.9% | 91,213 | +5.7% | 0.38% | +34.1% |
| Q1 2021 | $25,017,000 | +22.2% | 86,314 | +5.3% | 0.29% | +23.7% |
| Q4 2020 | $20,476,000 | +91.3% | 81,944 | +73.4% | 0.23% | +81.2% |
| Q3 2020 | $10,704,000 | +706.6% | 47,260 | +521.4% | 0.13% | +700.0% |
| Q2 2020 | $1,327,000 | +109.6% | 7,605 | +51.9% | 0.02% | +100.0% |
| Q1 2020 | $633,000 | – | 5,005 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| HealthInvest Partners AB | 149,612 | $12,334,000 | 5.66% |
| Van Berkom & Associates Inc. | 662,313 | $54,601,000 | 2.50% |
| Pembroke Management, LTD | 317,435 | $26,169,000 | 2.39% |
| Channing Capital Management, LLC | 685,581 | $56,519,000 | 2.37% |
| WESTPORT ADVISERS LLC | 150,000 | $12,366,000 | 2.28% |
| FLPUTNAM INVESTMENT MANAGEMENT CO | 232,074 | $19,132,000 | 2.27% |
| Hood River Capital Management LLC | 185,393 | $15,284,000 | 2.04% |
| Hodges Capital Management Inc. | 390,056 | $32,156,000 | 1.56% |
| Ariel Investments | 1,464,130 | $120,703,000 | 1.52% |
| Copper Rock Capital Partners, LLC | 240,615 | $19,836,000 | 1.50% |